Investor service announcement no. 5/2011



To: NASDAQ OMX Copenhagen
Hørsholm, Denmark, August 16, 2011






Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report
for first half 2011 - results from January 1 to June 30, 2011



Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for
first half 2011 on Wednesday August 17, 2011 after 05:00 PM. Veloxis'
Management will host an accompanying conference call to discuss the financial
results on Thursday August 18, 2011 at 03.00 PM CET (Denmark); 02:00 PM GMT
(London); 09:00 AM ET (New York) and 06:00 AM PT (San Francisco).


To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25 Denmark Local

+1 212 444 0481 USA Local

+44 (0)1452 555 566 UK Local

Conference ID: 90738320


An audio cast of the conference will be available on www.veloxis.com.



For more information, please contact:



John Weinberg, M.D. Johnny Stilou
SVP, Commercial Operations & Investor Relations Chief Financial Officer
Tlf: +1 908 304 3389 Tlf: +45 2055 3852
Email: [email protected] Email: [email protected]


Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis' efforts to develop a product
portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.


For further information, please visit www.veloxis.com.

160811 Veloxis Pharmaceuticals to Host Q2 2011 call.pdf